Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
More on this study > >
FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC
October 21st 2024The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.
Read More